Research Topics
Genomes and GenesSpecies | Ana OsorioSummaryCountry: Spain Publications
| Collaborators
|
Detail Information
Publications
Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer familiesAna Osorio
Human Genetics Group, Human Cancer Genetics Programme, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, C Melchor Fernandez Almagro 3, Madrid, Spain
Hum Mol Genet 21:2889-98. 2012....
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2Anna Marie Mulligan
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, 2 Worts Causeway, Cambridge, CB1 8RN, UK
Breast Cancer Res 13:R110. 2011..It is currently unknown how these alleles are associated with different breast cancer subtypes in BRCA1 and BRCA2 mutation carriers defined by estrogen (ER) or progesterone receptor (PR) status of the tumour...
Exploring the link between MORF4L1 and risk of breast cancerGriselda Martrat
Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
Breast Cancer Res 13:R40. 2011..To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens...
Over-representation of two specific haplotypes among chromosomes harbouring BRCA1 mutationsAna Osorio
Department of Human Genetics, Spanish National Cancer Center, Madrid, Spain
Eur J Hum Genet 11:489-92. 2003..These findings may have important consequences for the selection of families with higher probabilities of carrying mutations in the BRCA1 gene...
The breast cancer low-penetrance allele 1100delC in the CHEK2 gene is not present in Spanish familial breast cancer populationAna Osorio
Department of Human Genetics, Spanish National Cancer Center, Madrid, Spain
Int J Cancer 108:54-6. 2004..However, our results suggest that this variant is absent or very infrequent in our population, making its screening irrelevant from the practical point of view...
A haplotype containing the p53 polymorphisms Ins16bp and Arg72Pro modifies cancer risk in BRCA2 mutation carriersA Osorio
Department of Human Genetics, Spanish National Cancer Center, Madrid, Spain
Hum Mutat 27:242-8. 2006..Our results revealed a decrease in p53 apoptotic rate associated with the No Ins-72Pro haplotype...
Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor informationA Osorio
Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Centre, Madrid, Spain
Hum Mutat 28:477-85. 2007..We found that combining this relatively easily collected information can be sufficient to classify variants as pathogenic or neutral if tumors from at least three carriers of the same variant can be collected and analyzed...
Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibilityAna Osorio
Group of Human Genetics, Human Cancer Genetics Programme, C Melchor Fernandez Almagro 3, Madrid, 28029, Spain
Breast Cancer Res Treat 113:371-6. 2009..Our analysis suggests that RAP80 and CCDC98 do not play an important role as high penetrance breast cancer susceptibility genes...
An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriersA Osorio
Human Cancer Genetics Programme, Human Genetics Group, Spanish National Cancer Centre, Madrid, Spain
Br J Cancer 99:974-7. 2008..In this study, we have evaluated this association in a series of 2932 BRCA1/2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2...
Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancerAna Osorio
Department of Human Genetics, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Int J Cancer 99:305-9. 2002....
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio
Human Genetics Group, Spanish National Cancer Research Centre, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Br J Cancer 101:2048-54. 2009....
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2A Osorio
Human Genetics Group, Spanish National Cancer Centre, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Br J Cancer 104:1356-61. 2011..In this study, we have evaluated the XRCC1 gene that participates in the BER pathway, as phenotypic modifier of BRCA1 and BRCA2...
The variant E233G of the RAD51D gene could be a low-penetrance allele in high-risk breast cancer families without BRCA1/2 mutationsRaquel Rodríguez-López
Department of Human Genetics, Spanish National Cancer Centre, C Melchior Fernandez Almagro 3, 28029 Madrid, Spain
Int J Cancer 110:845-9. 2004..This suggests a role for E233G as a low-penetrance susceptibility gene in the specific subgroup of high-risk familial breast cancer cases that are not related to BRCA1/2...
No mutations in the XRCC2 gene in BRCA1/2-negative high-risk breast cancer familiesRaquel Rodríguez-López
Department of Human Genetics, Spanish National Cancer Center, Madrid, Spain
Int J Cancer 103:136-7. 2003
Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer familiesMaria J Garcia
Group of Human Genetics, Human Cancer Genetics Program, Spanish National Cancer Centre, CNIO, Madrid, Spain
Breast Cancer Res Treat 113:545-51. 2009....
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriersRoger L Milne
Grupo de Epidemiología Genética y Molecular, Programa de Genética del Cáncer Humano, Centro Nacional de Investigaciones Oncologicas CNIO, C Melchor Fernández Almagro, Madrid, Spain
Breast Cancer Res Treat 119:221-32. 2010..Whether later age at first birth is also protective for ovarian cancer in mutation carriers requires further confirmation...
Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testingMiguel de la Hoya
Laboratory of Molecular Oncology, Hospital Universitario San Carlos, Madrid, Spain
Int J Cancer 97:466-71. 2002..4% and 79%, respectively (probability cutoff of 30%). The findings of our work may be a useful tool for increasing the cost-effectiveness of genetic testing in familial cancer clinics...
Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX familiesEmiliano Honrado
Department of Human Genetics, Spanish National Cancer Centre, Melchor Fernandez Almagro 3, Madrid, Spain
Mod Pathol 20:1298-306. 2007..In addition we have defined a subset of them that have somatic inactivation of the BRCA1 gene...
The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in SpainRoger L Milne
Unidad de Genotipación CEGEN and Grupo de Genética Humana, Programa de Genética del Cáncer Humano, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
Clin Cancer Res 14:2861-9. 2008..We aimed to estimate these penetrances for women attending genetic counseling units in Spain...
Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predispositionMaria J Garcia
Group of Human Genetics, Human Cancer Genetics Program, Spanish National Cancer Centre CNIO, C Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Carcinogenesis 30:1898-902. 2009..Our results rule out a major role of FANCI, FANCL and FANCM in familial breast cancer susceptibility, suggesting that among the 13 known FA genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition...
The accumulation of specific amplifications characterizes two different genomic pathways of evolution of familial breast tumorsLorenzo Melchor
Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Center, Madrid, Spain
Clin Cancer Res 11:8577-84. 2005..CONCLUSION: In summary, our data suggest the existence of two different patterns of evolution, probably common to familial and sporadic breast tumors...
Clustering of cancer-related mutations in a subset of BRCA1 alleles: a study in the Spanish populationMiguel de la Hoya
Laboratory of Molecular Oncology, Hospital Universitario San Carlos, Madrid, Spain
Int J Cancer 100:618-9. 2002..Further analysis involving a larger set of mutations and different populations are needed to clarify the relevance of this unexpected finding...
Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markersJose Palacios
Breast and Gynaecological Cancer Laboratory, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
Breast Cancer Res Treat 90:5-14. 2005....
Mutational analysis of telomere genes in BRCA1/2-negative breast cancer families with very short telomeresKira Yanowsky
Human Genetics Group, Spanish National Cancer Research Centre CNIO, Melchor Fernandez Almagro 3, 28029 Madrid, Spain
Breast Cancer Res Treat 134:1337-43. 2012..However, functional prediction analysis and control population studies of both variants ruled out its possible pathogenic role. Our results discard a major contribution of telomere-specific genes in hereditary breast cancer...
Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancerLorenzo Melchor
Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center CNIO, Madrid, Spain
Clin Cancer Res 13:7305-13. 2007....
Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriersJose Palacios
Laboratory of Breast and Gynecological Cancer, Immunohistological Unit, Centro Nacional de Investigaciones Oncologicas, 28029 Madrid, Spain
Clin Cancer Res 9:3606-14. 2003..Therefore, it is of major importance to define the morphological, immunohistochemical, and molecular features of this group of tumors to improve genetic testing and also gain further insight into the biological characteristics of tumors...
Genomic rearrangements at the BRCA1 locus in Spanish families with breast/ovarian cancerMiguel de la Hoya
, , Madrid, , Facultad de Medicina, Universidad de Valladolid, Spain
Clin Chem 52:1480-5. 2006..MLPA analysis of positive samples with an alternative set of probes, together with long-range PCR and real-time PCR, is a feasible approach to confirm results in cases in which LGR breakpoints have not been characterized...
Transcriptional characteristics of familial non-BRCA1/BRCA2 breast tumorsRicardo Fernández-Ramires
Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center CNIO and CIBERER, Madrid, Spain
Int J Cancer 128:2635-44. 2011....
Genetic anticipation is associated with telomere shortening in hereditary breast cancerBeatriz Martinez-Delgado
Human Genetics Group, Spanish National Cancer Research Centre CNIO, Madrid, Spain
PLoS Genet 7:e1002182. 2011..Our results provide evidence that telomere shortening is associated with earlier age of cancer onset in successive generations, suggesting that it might be a mechanism of genetic anticipation in hereditary breast cancer...
Mutant BRCA1 alleles transmission: different approaches and different biasesMiguel de la Hoya
Molecular Oncology Laboratory, , Madrid, Spain
Int J Cancer 113:166-7. 2005..In this report we propose different approaches to overcome such biases and we present additional data supporting a non-random transmission of BRCA1 mutant alleles...
A predictor based on the somatic genomic changes of the BRCA1/BRCA2 breast cancer tumors identifies the non-BRCA1/BRCA2 tumors with BRCA1 promoter hypermethylationSara Alvarez
Human Genetics Department, Molecular Pathology Programme, Spanish National Cancer Centre, c o Melchor Fernandez Almagro, 28029 Madrid, Spain
Clin Cancer Res 11:1146-53. 2005..This fact suggests that somatic BRCA1 inactivation could modify the profile of tumor progression in most of the BRCAX cases...
Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogeneMiljana Tanic
Human Genetics Group, Spanish National Cancer Research Centre CNIO, Madrid, Spain
PLoS ONE 7:e38847. 2012..In addition, we provide evidence that KRAS is a target of miR-30c, and that this miRNA suppresses breast cancer cell growth potentially through inhibition of KRAS signaling...
Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studiesAnna Gonzalez-Neira
Genotyping Unit, CeGen, Human Cancer Genetics Programme, Spanish National Cancer Centre, Spain
BMC Genomics 8:299. 2007....
Loss of the actin regulator HSPC300 results in clear cell renal cell carcinoma protection in Von Hippel-Lindau patientsAlberto Cascon
Hereditary Endocrine Cancer Group, Centro Nacional de Investigaciones Oncologicas CNIO, Madrid, Spain
Hum Mutat 28:613-21. 2007..These clinical and functional data indicate a relevant function of HSPC300 in tumor cell progression, and suggest future therapeutic strategies based upon the inhibition of HSPC300 in renal cell carcinoma and possibly on other cancers...
Molecular analysis of the BRCA2 gene in 16 breast/ovarian cancer Spanish familiesA Osorio
Department of Genetics, Fundacion Jimenez Diaz, Madrid, Spain
Clin Genet 54:142-7. 1998..All the families carrying the 936delAAAC mutation harboured part of a common haplotype shared by other reported carriers, suggesting a possible founder effect for this mutation...
Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutationsE Honrado
Human Genetics Group, Spanish National Cancer Centre CNIO, Madrid, Spain
Oncogene 25:5837-45. 2006..However, they represent an example showing how different mutations of the same gene may be associated with specific histological subtypes of cancer...
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility allelesFrancisco Javier Gracia-Aznárez
Human Genetics Group, Spanish National Cancer Centre CNIO, Madrid, Spain
PLoS ONE 8:e55681. 2013....
Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish familiesA Osorio
Department of Genetics, , Madrid, Spain
Br J Cancer 82:1266-70. 2000..Our results are in agreement with the idea that a great proportion of moderate-risk cancer families could be due to low penetrance susceptibility genes distinct from BRCA1 or BRCA2...
A rapid and easy method for multiple endocrine neoplasia type 1 mutation detection using conformation-sensitive gel electrophoresisCebrián Arancha
Department of Human Genetics, Molecular Pathology Program, Centro Nacional de Investigaciones Oncologicas, Madrid, Spain
J Hum Genet 47:190-5. 2002..Mutation screening of the MEN1 gene using CSGE was demonstrated to be a fast, simple, and inexpensive method to study patients suspected of having MEN1 disease...
Mutation analysis of the BRCA2 gene in breast/ovarian cancer Spanish families: identification of two new mutationsA Osorio
Department of Genetics, Fundacion Jimenez Diaz, Madrid, Spain
Cancer Lett 121:115-8. 1997..3%), including two with male breast cancer. Three of the mutations were frameshift and one was a missense. Two of the mutations have been previously published and two are new mutations...
Gene expression profiling integrated into network modelling reveals heterogeneity in the mechanisms of BRCA1 tumorigenesisR Fernández-Ramires
Spanish National Cancer Center CNIO and CIBERER, Madrid, Spain
Br J Cancer 101:1469-80. 2009..Here, we describe molecular signatures that define BRCA1 subclasses depending on the expression of the gene encoding for oestrogen receptor, ESR1...
Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypesL Melchor
Human Genetics Group, Human Cancer Genetics Program, Spanish National Cancer Center CNIO, Madrid, Spain
Oncogene 27:3165-75. 2008..Our data are similar to those obtained in SBC studies, highlighting the existence of distinct genetic pathways of tumor evolution, common to both SBC and FBC...
Molecular analysis of the six most recurrent mutations in the BRCA1 gene in 87 Spanish breast/ovarian cancer familiesA Osorio
Department of Genetics, Fundacion Jimenez Diaz, Madrid, Spain
Cancer Lett 123:153-8. 1998..Our results suggest that these six mutations are not specially recurrent in the Spanish population and that differences in the geographical origin of the families can influence the type and proportion of mutations identified...
A region of allelic imbalance in 1q31-32 in primary breast cancer coincides with a recombination hot spotJ Benitez
Departamento Genética, Fundacion Jimenez Diaz, Madrid, Spain
Cancer Res 57:4217-20. 1997..Most important, the critical region of AI coincides with a female hot spot of recombination, suggesting a possible correlation between the two regions...
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriersAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, UK
Am J Hum Genet 82:937-48. 2008....
Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from SpainBerta Campos
, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hum Mutat 21:452. 2003..1 cM. Our results suggest that these families shared a common ancestry with BRCA2 9254del5, which is a founder mutation originating in the Northeast Spanish, with an estimated age of 92 (95% CI 56-141) generations...
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studiesAntonis C Antoniou
Cancer Research UK, Genetic Epidemiology Unit, Strangeways Research Laboratory, Cambridge, CB1 8RN, UK
Am J Hum Genet 81:1186-200. 2007..Thus, 135G-->C may modify the risk of breast cancer in BRCA2 mutation carriers by altering the expression of RAD51. RAD51 is the first gene to be reliably identified as a modifier of risk among BRCA1/2 mutation carriers...
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort StudyJenny Chang-Claude
Division of Cancer Epidemiology, German Cancer Research Center, Im Neuenheimer Feld 280 69120 Heidelberg, Germany
Cancer Epidemiol Biomarkers Prev 16:740-6. 2007..Early menarche and late menopause are important risk factors for breast cancer, but their effects on breast cancer risk in BRCA1 and BRCA2 carriers are unknown...
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effectsOrland Diez
Servei de Genètica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Hum Mutat 22:301-12. 2003..Knowledge of the spectrum of mutations and their geographical distribution in Spain will allow a more effective detection strategy in countries with large Spanish populations...
Accurate prediction of BRCA1 and BRCA2 heterozygous genotype using expression profiling after induced DNA damageZsofia Kote-Jarai
Translational Cancer Genetics Team, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
Clin Cancer Res 12:3896-901. 2006..We aimed to establish if BRCA1/BRCA2 mutation carriers could be distinguished from noncarriers based on expression profiling of normal cells...
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumorsEmiliano Honrado
, 3 28029 Madrid, Spain
J Clin Oncol 23:7503-11. 2005..CONCLUSION: Our results suggest that BRCA2 tumors demonstrate more cytoplasmic and less nuclear RAD51 staining, and increased CHEK2 staining. This pattern may distinguish BRCA2 from familial non-BRCA1/2 tumors...
Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancerJose Palacios
J Natl Cancer Inst 96:712-4; author reply 714. 2004
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage ConsortiumDeborah Thompson
CRC Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Cambridge CB1 4RN, United Kingdom
Proc Natl Acad Sci U S A 99:827-31. 2002..65 was -11.0]. We conclude that, if a susceptibility gene does exist at this locus, it can only account for a small proportion of non-BRCA1/2 families with multiple cases of early-onset breast cancer...
